Medigen Vaccine Biologics Corp. (MVC), a subsidiary of Medigen Biotechnology Corp. (Medigen), has signed a memorandum of understanding (MOU) with Switzerland-based MABXIENCE to jointly participate in an international biosimilar collaboration project. The parties plan to co-develop biopharmaceutical products with strong market potential.  Under the terms of the MOU, MVC intends to obtain exclusive commercial rights in major Asian countries and to receive a technology transfer for biosimilar manufacturing.  A formal contract will subsequently be signed, in compliance with applicable legal and regulatory requirements. MVC expects this project to serve as a starting point for expanding beyond its existing cell culture-based vaccine business into biosimilar development, thereby establishing a more comprehensive presence in the biopharmaceutical sector. 

About MABXIENCE and the CHEMO Group 

Founded in 2009 in Europe, MABXIENCE is a wholly owned subsidiary of the CHEMO Group, focusing on the group's biopharmaceutical business. The company operates EU-certified GMP manufacturing facilities and is actively developing multiple biosimilar products. 

MABXIENCE's parent company, the CHEMO Group, was founded in 1977 and is headquartered in Madrid, Spain. CHEMO operates across three core sectors: active pharmaceutical ingredients and finished dosage forms, branded pharmaceuticals, and biotechnology. With annual revenues exceeding €1 billion, CHEMO employs more than 5,000 people worldwide and has a presence in 40 countries. 

Related Information: 

1.MABXIENCE 
2.CHEMO Gruop